ANTIVIRAL TREATMENT OPTIONS FOR COVID-19 BY REDUCTION OF VIRAL LOAD AND VIRAL SHEDDING

Chandrika Murugaiah1*, Liew Sat Lin Constance1, Hassanain Al-Talib2, Mehru Nisha3, Tunung Robin4, Tuan Zainazor Tuan Chilek5, Atif Amin Baig6, Rhanye Mac Guad4, May Zaw Soe1, Abm Tofazzal Hossain1, Falah Abbas Mohamad Salih3, Mustafa al Shagga7

1Faculty of Medicine and Health Sciences, Universiti Malaysia Sabah
2Laboratory Medical Science Cluster, Faculty of Medicine, Universiti Teknologi MARA (UiTM)
3Clinical Laboratory Science Section, University Kuala Lumpur
4Universiti Putra Malaysia Bintulu Sarawak Campus
5Faculty of Fisheries and Food Science, University Malaysia Terengganu
6Faculty of Medical Sciences, University Sultan Zainal Abidin
7University of Nottingham Malaysia

Article Info: Received 20 May 2020; Accepted 10 June 2020
DOI: https://doi.org/10.32553/ijmbs.v4i6.1201
Corresponding author: Chandrika Murugaiah
Conflict of interest: No conflict of interest.

Summary

The coronavirus disease 2019 (COVID-19) virus is a public health emergency of international concern, without known effective pharmaceutical treatment so far. It is difficult to treat infected patients who are experiencing acute respiratory failure, liver or cardiac injury, gastroenteritis and many other complications without any drug recommendation. Reducing the viral load is the most important key for Covid-19 treatment, where complication due to infection is highly correlated with the number of viral particles present in the lung and other organs of the patient. Most antivirals are effective against a wide range of viruses, where they inhibit viral development. Some of the possible antiviral treatment options for COVID-19 could be discovered from flu viral treatment that had led to quick respiratory illness recovery through reduction of viral load and viral shedding.

Baloxavir marboxil

Baloxavir marboxil is use in treatment of influenza A and influenza B flu. Baloxavir has reduced the viral load 1 day after initiation of the regimen; evidenced found in patients with uncomplicated influenza from two randomized, double-blind, controlled trials [1].

DAS181

DAS181 inhibits parainfluenza infection to respiratory cells, also protects human lung tissue and pneumocytes from avian influenza virus H5N1. Significant decreased in viral load and viral shedding in participants infected with influenza; evidence from trial encompassing 3 influenza seasons from 2009-2011 in both the Northern and Southern Hemispheres involving 177 infected participants [2].

Oseltamivir

Oseltamivir is Influenza-specific dosing for Tamiflu. Less viral shedding and improved health was found in oseltamivir treated adults with naturally acquired influenza; evidence from 726 healthy non-immunised adults with febrile influenza-like illness in a randomised controlled trial [3].

Recommendations for future research

This article suggests three potential antiviral which should be considered in the clinical management and treatment for covid-19. But there could be more antiviral candidate that could reduce viral load and viral shedding which is not discussed here. Future research should include clinical trials on these candidates individually and in combination to access patient recovery from COVID-9 complications.

References
